Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
GlaxoSmithKline
Discovery of HM74A, target for nicotinic acid, may lead to discovery of drug
May 14th, 2003
Discovery of HM74A, target for nicotinic acid, may lead to discovery of superior drug molecules to treat dyslipidemia. "Nicotinic acid has been used clinically for over 40 years in the treatment of dyslipidemia producing a desirable normalization of a range of cardiovascular risk factors, including a marked elevation of high density lipoprotein and a reduction in mortality. "The precise mechanism of action of nicotinic acid is unknown, although it is believed that activation of a Gi -G protein-coupled receptor may contribute. "Utilizing available information on the tissue distribution of nicotinic acid receptors, we...
Source: Biotech Week (2003-05-14)
|
